Arsanis, Inc. (ASNS) Hits All-Time Low

June 29, 2018 - By Daniel Mitchell

Arsanis, Inc. (NASDAQ:ASNS) reached all time low on Jun, 29 with $3.48 PT or 7.00 % below the last $3.74 share price. Barchart.com published the all time low. The company has $53.46M market cap. At $3.48 PT, the company’s valuation could be $3.74M less.

ASNS reached $3.74 during the last trading session after $0.26 change.Arsanis, Inc. is after having 0.00% since June 29, 2017. ASNS has 289,279 volume or 429.35% up from normal. ASNS underperformed by 12.57% the S&P500.

Arsanis, Inc. (NASDAQ:ASNS)’s quarterly earnings will be reported on August, 9., Faxor reports. 6.76 % negative EPS growth is what Wall Street’s forecasts after $-0.74 reported EPS previous quarter.

For more Arsanis, Inc. (NASDAQ:ASNS) news released recently go to: Benzinga.com, Seekingalpha.com, Schaeffersresearch.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “50 Biggest Movers From Friday” released on June 25, 2018, “Arsanis to discontinue Phase 2 trial of pneumonia treatment” on June 28, 2018, “2 Healthcare Stocks Getting Buried; Option Bulls Cheer MRVL Spike” with a publish date: June 28, 2018, “Pre-Open Movers 06/28: (DRRX) (ZSAN) (CAVM) Higher; (ASNS) (PIR) (WBA) Lower (more…)” and the last “Mid-Morning Market Update: Markets Edge Lower; Walgreens Beats Q3 Views” with publication date: June 28, 2018.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody immunotherapies to address serious infectious diseases.The company has $53.46 million market cap. The Company’s lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.Currently it has negative earnings. The company's preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis, Inc. (NASDAQ:ASNS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: